Menstrual- and gender-dependent variations in circulating IL-1 agonists, antagonists, and binding proteins.

Menstrual- and gender-dependent variations in circulating IL-1 agonists, antagonists, and binding proteins.
复制标题

循环 IL-1 激动剂、拮抗剂和结合蛋白的月经和性别依赖性变化。

DOI:
10.1002/jlb.63.1.117
复制
发表时间:
1998
影响因子:
5.5
通讯作者:
Lynch,EA
Lynch,EA
中科院分区:
医学3区
文献类型:
--
作者:
Cannon,JG;Abad,LW;Vannier,E;Lynch,EA

文献摘要

相似文献

为了验证白细胞介素-1 β(IL-1 β)结合蛋白存在性别差异以及这些结合蛋白影响IL-1 β和IL-1 Ra免疫测定的假设,将125 I标记的IL-1 β加入人血浆样品中,然后进行层析。男性(n= 6)、卵泡期女性(n = 6)和黄体期女性中高分子量峰洗脱的总放射性百分比分别为21.0 ± 0.8、19.1 ± 0.9和18.0 ± 0.8(n= 6;男性vs女性,P= 0.032;卵泡vs黄体,P= 0.035),并与血浆sIL-1 RII浓度相关(r= 0.647,P = 0.007)。血浆IL-1 β免疫反应性与同时的细胞分泌率不一致,部分原因是sIL-1 RII干扰IL-1 β测定。血浆IL-1 Ra水平和细胞分泌率之间的对应关系,观察后,样品的系列稀释。这些结果表明,血浆IL-1 β结合能力在男性和女性之间存在差异,sIL-1 RII是一个主要的影响因素。此外,将血浆IL-1亚型免疫反应性与功能性测量(示踪剂结合)或分离细胞的同时释放相关,可以了解血浆中可能存在的测定干扰。
This study tested the hypotheses that sex-related differences in circulating binding proteins for interleukin-1 β (IL-1 β) exist and that these binding proteins affect immunoassays for IL-1 β and IL-1Ra.125I-labeled IL-1 β was added to human plasma samples, then chromatographed. The percentages of total radioactivity eluting in a high-molecular-weight peak were 21.0 + 0.8 for men (n= 6), 19.1 ± 0.9 for follicular phase women (n= 6), and 18.0 ± 0.8 in luteal phase women (n= 6; men vs. women,P= 0.032; follicular vs. luteal,P= 0.035), and correlated with plasma sIL-1RII concentrations (r= 0.647,P= 0.007). Plasma IL-1 β immunoreactivity did not correspond to concurrent cellular secretion rates due, in part, to interference in the IL-1 β assay by sIL-1RII. Correspondence between plasma IL-1Ra levels and cellular secretion rates was observed only after serial dilutions of the samples. These results indicate that plasma IL-1 β binding capacity differs between men and women and that sIL-1RII is a major contributing factor. Furthermore, relating plasma IL-1 isoform immunoreactivity to functional measures (tracer binding) or concurrent release by isolated cells can lead to insights about assay interferences that may exist in plasma.